In high BCL-2-expressing acute leukemia cells with resistance to TRAIL, XIAP inhibitors were able to induce cleavage of BCL-2 proteins and promote MOMP through conformational change of BAK, further enhancing TRAIL-induced apoptosis [62]. Here, BCL2 is linked to acute leukemia.